Alchemab Therapeutics
Cambridge, England, United Kingdom · Biotechnology, Health Care, Pharmaceutical · 53 employees
Alchemab is harnessing the naturally protective power of patient antibodies to keep people free of hard-to-treat disease in a unique and transformative approach to drug discovery and development. Alchemab takes an unbiased and function-first approach using three complementary processes and cutting-edge technologies to identify naturally protective antibodies. Alchemab’s engine is enabled throug
Funding history
- Series series a — Undisclosed — Sep 2025
Recent signals
- Mar 17, 2026: Alchemab Therapeutics Appoints Ulrich Wendt as Chief Business Officer
- Sep 09, 2025: Raised funding in Series series a
- May 06, 2025: Alchemab Therapeutics signs $415m licensing agreement for ATLX-1282 with Eli Lilly and Company
- Sep 12, 2024: Jane Osbourn Succeeds Young Kwon as CEO of Alchemab Therapeutics
See plans & pricing → Track Alchemab Therapeutics’s funding, hiring, and signals — with verified contacts — on Fundz.